From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

SkinBioTherapeutics – ‘Business Update’, high margin profit potential moving materially closer

By Tom Winnifrith & Steve Moore | Friday 20 August 2021


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


SkinBioTherapeutics (SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30th June year-end cash totalled £4.6 million. Sounds good.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Thursday »

LUCE

Luceco – a trading recovery Buy?...

 

Quiz

The ShareProphets Sunday Pub Quiz #260

Thursday »

TM1

Rat. Sinking Ship. Technology Minerals

Wednesday »

Bearcast

Tom Winnifrith Bearcast: Another red flag at Cirata

 

Quiz

The ShareProphets Sunday Pub Quiz #259

 

DPP

DP Poland: a recovery buy at 10.75p?

 

Quiz

The ShareProphets Sunday Pub Quiz #258

 

Tom

Photo Article from Sharestock: tea

Time left: 18:40:32